On Wednesday, Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE)’s shares declined -5.08% to $1.87.
On April 20, Yingli Green Energy Hold. Co. Ltd. declared that it has obtained an RMB300 million (USD48 million) financing facility for a 50 megawatt (MW) PV power plant in China. The 10-year direct financing lease for the project’s development and construction was offered by CGN International Finance Leasing, a wholly-owned partner of China General Nuclear Power Group (CGN).
Located in Handan City, Hebei Province, the 50 MW PV power plant is predictable to generate about 54 million kilowatt-hours of solar electricity annually, offsetting over 50,000 tons of carbon emissions. Construction and interconnection of the project are predictable to be accomplished by the end of May 2015.
“We are happy to start our relationship with CGN International Finance Leasing, and believe that our partnership is a key breakthrough for Yingli’s downstream business development,” commented Mr. Liansheng Miao, Chairman and Chief Executive Officer of Yingli Green Energy. “We anticipate that more Chinese financial institutions will ramp up activities in PV project development moving forward.”
Yingli Green Energy Holding Company Limited, together with its auxiliaries, designs, develops, manufacture, markets, sells, and installs photovoltaic products in the Peoples Republic of China. It offers PV cells, PV modules, and integrated PV systems; and polysilicon ingots and blocks, and polysilicon wafers, in addition to develops and operates solar projects.
Gold Fields Limited (ADR) (NYSE:GFI)’s shares dropped -4.99% to $4.19, during the last trading session on Wednesday.
Yesterday, Gold Fields Limited (GFI), will publish its results for the quarter ended 31 March 2015 on the company’s website (http://www.goldfields.co.za) at 7:05am (SA time) on Thursday, 7 May 2015.
A telephone conference call with our CEO to talk about the results has been planned at the times indicated below:
Johannesburg : 16:00 hours
For United Kingdom : 15:00 hours (GMT)
For North America : 10:00 hours, (EST)
Gold Fields Limited operates as a gold mining company. The company engages in the exploration, extraction, processing, and smelting of gold and copper properties. It holds interests in eight operating mines in South Africa, Ghana, Australia, and Peru. The company has total gold mineral reserves of about 48.1 million ounces and mineral resources of about 108.3 million ounces. Gold Fields Limited was founded in 1887 and is based in Sandton, South Africa.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), ended its Wednesday’s trading session with -4.76% loss, and closed at $0.60.
On April 16, AEterna Zentaris (AEZS), declared that it has filed an application for a patent on a novel method of manufacturing zoptarelin doxorubicin, its hybrid cytotoxic molecule that is the subject of a pivotal ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 clinical study in women with advanced, recurrent or metastatic endometrial cancer who have progressed and who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or first-line treatment). The claimed manufacturing process is predictable to result in a noteworthy reduction in the cost of goods sold, providing a stronger competitive position for the Company.
Zoptarelin doxorubicin is a complex molecule that combines a synthetic peptide carrier with doxorubicin, a well-known chemotherapy agent. The synthetic peptide carrier is a Luteinizing Hormone Releasing Hormone (“LHRH”) agonist, a modified natural hormone with affinity for the LHRH receptor. The design of the compound allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH receptor-positive tumors. Potential benefits of this targeted approach comprise a better efficacy and a more favorable safety profile with lower incidence and severity of side effects as contrast to doxorubicin alone.
Because zoptarelin doxorubicin is a complex molecule, it is expensive to synthesize. The patent application, which is entitled “Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters”, may, if granted, make it difficult for generic manufacturers to produce the compound on a financially feasible basis after the Company’s composition‑of-matter patent on zoptarelin doxorubicin expires.
The Company owns all rights to the new process. The Company intends to file a PCT patent application in January 2016, claiming priority of the filed EP patent application.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The company’s product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
